Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions

Schwarz, Stephan; Rechenmacher, Michael; Filbeck, Tomas; Knuechel, Ruth; Blaszyk, Hagen; Hartmann, Arndt; Brockhoff, Gero

doi:10.1136/jcp.2007.049684

Cited by 39 publications

(34 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More extensive investigation of CIS may reveal clinical circumstances for which this method is particularly useful. For example, applying the UV technique to paraffin-embedded biopsy samples, Schwarz and colleagues [151] found polysomy of one or more chromosomes in 91% of CIS cases (30/33) and deletion of 9p21 in 74% (22/31), leading the authors to propose this technique as an aid for resolution of histologically challenging biopsies as well as cytologic samples.…”

Section: Molecular Markers For Early Detection Of Tccmentioning

confidence: 96%

Bladder cancer: translating molecular genetic insights into clinical practice

Liu¹,

Zhang²,

MacLennan³

et al. 2011

Human Pathology

168

124

View full text Add to dashboard Cite

Section: Molecular Markers For Early Detection Of Tccmentioning

confidence: 96%

Bladder cancer: translating molecular genetic insights into clinical practice

Liu¹,

Zhang²,

MacLennan³

et al. 2011

Human Pathology

168

124

View full text Add to dashboard Cite

“…TMAs can also be constructed from flat urothelial lesions. Schwarz et al [40] constructed a TMA containing 29 samples of normal urothelium and 86 flat urothelial lesions (hyperplasia, reactive atypia, dysplasia and carcinoma in situ) ( Figure 1). Multicolour FISH using the Urovysion † test showed that polysomy and/or deletions of the chromosomal region 9p21 could be demonstrated in 50Á90% of cells in urothelial dysplasias and carcinoma in situ, but only infrequently in urothelial hyperplasias, reactive lesions or normal urothelium.…”

Section: Fluorescence In Situ Studies Using Tissue Microarraysmentioning

confidence: 99%

Tissue microarray studies in bladder cancer

Hartmann

2008

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

The introduction of tissue microarray (TMA) methodology 10 years ago has provided a valuable tool for high-throughput genomic and proteomic analyses. Using this method hundreds of minute tissue samples can be investigated on one microscopic glass slide. Several studies demonstrated that these small tissue areas are representative for the entire tumour block and can provide reliable information on the relation of molecular markers and clinical outcome of the patient. Types of TMA used in bladder cancer research include defined clinical case series, stage-specific series (e.g. pT1), stage progression series, TMAs containing all specimens from clinical trials for specific therapies, flat (pre)neoplastic lesions, cell culture pellets and mouse model TMAs. The TMA technique has frequently been used in bladder cancer research to evaluate immunohistochemical candidate markers for prognosis and to reveal the amplification frequency of candidate oncogenes in regions with copy number alterations detected by comparative genomic hybridization and array-based methods. In addition, multimarker expression studies of several specific biological functions (e.g. apoptosis or cell-cycle proteins) or signal transduction pathways have been performed. TMAs are also used for validation of array-based gene expression studies on the protein level. TMA technology represents a crucial technique for translating new information on molecular changes in bladder cancer into clinical practice.

show abstract

“…Insbesondere wenn es sich um das Monitoring von Patienten, die eine High-grade-Läsion hatten handelt oder solche, die dafür ein Risiko haben, hat sich das FISHunterstützte Monitoring dieser Patienten bewährt [3]. Diese Daten werden auch durch den Einsatz der UroVysion®-Probe am Schnittpräparat belegt [10] [6]). Während in den bisherigen Abschnitten betont wurde, wo der Einsatz von UroVysion® sinnvoll ist, sei abschließend noch ergänzt, dass bei eindeutig positiver Zytologie eine FISH in der bisherigen Zusammensetzung der Sonden keine Zusatzinformation bringt.…”

Section: Indikationen Mit Algorithmus Für Die Praxisunclassified

Uringebundene Marker mit besonderer Berücksichtigung der Fluoreszenz-in-situ-Hybridisierung (FISH)

Lindemann-Docter

Gaisa

Smeets

et al. 2011

Urologe

View full text Add to dashboard Cite

Patient care with noninvasive or minimally invasive methods is appealing for the patient. It has to be assessed in terms of validity to guarantee improvement of patient care. Urine cytology for the detection of tumour cells can be considered a valid method since its specificity and sensitivity is high when high-grade tumour cells are sought. High-grade tumour cells are considered the clinically most relevant finding in urine specimens. Fluorescent in situ hybridization of interphase nuclei on centromeric and gene loci has been optimized for urothelial carcinoma and increases the sensitivity of tumour findings. It also gives a valid chance to adapt the number of cystoscopies in the follow-up of bladder cancer patients more individually.

show abstract

Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions

Abstract: UroVysion fluorescence in situ hybridisation is a valuable tool for the detection of genetically unstable flat urothelial lesions, and can help to resolve difficult cases, particularly the differential diagnosis of reactive atypia and dysplasia.

Cited by 39 publications

References 40 publications

Bladder cancer: translating molecular genetic insights into clinical practice

Bladder cancer: translating molecular genetic insights into clinical practice

Tissue microarray studies in bladder cancer

Uringebundene Marker mit besonderer Berücksichtigung der Fluoreszenz-in-situ-Hybridisierung (FISH)

Contact Info

Product

Resources

About